Established in 2003 by Prof. Raymond Kaempfer and Dr. Gila Arad from the faculty of medicine at the Hebrew University, Atox Bio is a late stage biotechnology company that develops novel immunomodulators for critically ill patients.
AB103, Atox Bio’s lead product, is initially being developed to treat Necrotizing Soft Tissue Infections (NSTI), a rare, life threatening infection with high morbidity and mortality.
AB103 is currently being studied in ACCUTE (AB103 Clinical Composite endpoint StUdy in necrotizing soft Tissue InfEctions) , a phase 3 clinical trial evaluating its efficacy in patient with NSTI. Previously, AB103 completed a phase 2 study in NSTI. Results demonstrated that patients treated with AB103 had a meaningful improvement across multiple end points.
AB103 was granted Fast Track status and Orphan Drug designation from the FDA as well as Orphan Medicinal Product designation from the European Commission.
AB103 development is supported by a contract from BARDA (Biomedical Advanced Research and Development Authority).